Innovators in Hemoglobinopathies Academic Career Development Award (K07)

The summary for the Innovators in Hemoglobinopathies Academic Career Development Award (K07) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Innovators in Hemoglobinopathies Academic Career Development Award (K07): Purpose. The purpose of the NHLBI Innovators in Hemoglobinopathies Academic Career Development Award is to provide support for salary and research costs for up to 4 years for individuals with medical or doctoral degrees in clinical fields who are not fully established investigators and who want to pursue research careers in sickle cell disease and/or the thalassemias. The primary objective of this program is to advance the research career development of clinician scientists who have implemented innovative programs for patients with sickle cell disease and/or the thalassemias but have not been on a research track. These awards will provide support to clinician scientists who would not be eligible for other NHLBI mentored K awards, i.e., K23, K01, K08, or K25 (http://www.nhlbi.nih.gov/funding/training/redbook/newintro.htm). Prospective Candidates are encouraged to contact the NHLBI staff for specific programmatic and budgetary information (see Section VII. Agency Contacts of this FOA). Mechanism of Support. This FOA will utilize the K07 award mechanism. Candidates must commit a minimum of nine person months (75%) effort to activities covered under the award. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit $2.484 million total costs in FY2011 to support meritorious projects solicited through this RFA. The NHLBI expects to award 6 grants for a total of $9,936,000 in funds over the 4-year project period.
Federal Grant Title: Innovators in Hemoglobinopathies Academic Career Development Award (K07)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HL-10-021
Type of Funding: Grant
CFDA Numbers: 93.839
CFDA Descriptions: Blood Diseases and Resources Research
Current Application Deadline: Sep 14, 2010
Original Application Deadline: Sep 14, 2010
Posted Date: Jun 29, 2010
Creation Date: Jun 29, 2010
Archive Date: Oct 15, 2010
Total Program Funding: $2,484,000
Maximum Federal Grant Award: $414,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) .
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...
Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)
Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional)
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia ...
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia ...
Improved Therapy for Hemophilia and Hereditary Bleeding Disorders
Clinical Hematology Research Career Development Program (K12)
Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com